Company News

PREFECT Trial Outcomes Demonstrate MyoStrain® Ability to Detect & Predict Early Cardiotoxicity in Cancer Patients Undergoing Chemotherapy

  • MyoStrain successfully quantified early subclinical cardiotoxicity caused by cancer therapy
  • MyoStrain accurately identified cancer patients at risk of cardiotoxicity, demonstrating its prognostic value as a predictor of cardiotoxicity
  • The study highlights the clinical utility of MyoStrain as a powerful tool that may help clinicians provide optimal cardio-protection during cancer therapy
June 21, 2021
Company News

MORRISVILLE, N.C., June 21, 2021 /PRNewswire/ -- A new pivotal article validated Myocardial Solutions technology MyoStrain® (fSENC) for the early detection and prediction of cardiotoxicity (heart damage). The article was published in Circulation: Cardiovascular Imaging, Journal of the American Heart Association–one of the most prestigious cardiology journals, and highlights MyoStrain’s diagnostic and prognostic value as an accurate and sensitive management tool that may help clinicians protect cancer patient heart health during chemotherapy.[1]

The study presented key data from the PREFECT trial (NCT03543228), where observers used MyoStrain to take baseline heart assessments of 61 cancer patients and observe changes in each patient’s heart function over a 2-year period. Results showed that MyoStrain, via the MyoHealth™ Score, was able to successfully monitor patients as they underwent cancer treatment and detect early signs of cardiotoxicity where traditional metrics, such as left-ventricular ejection faction (LVEF), could not.[1]

Professor Susan Dent, MD, Medical Oncologist, Member of the Duke Cancer Institute, Co-Director of Duke Cardio-Oncology Program and study author, stated: “MyoStrain bridges a crucial gap in oncology and cardiology care. Thanks to the advances in oncology care, cancer is more treatable now than ever before. While clinical outcomes for cancer patients have improved, there is increasing concern about the potential short- and long-term side effects of these treatments, including the potentially detrimental impact they may have on the heart.

This study demonstrates that MyoStrain, via MyoHealth, can be an effective clinical diagnostic tool not only to predict and detect cardiotoxicity early, but also to protect cancer patients' heart health throughout the course of therapy. Oncologists and cardiologists can implement individualized cardio-protective care plans from baseline and throughout cancer treatment to decrease the risk of cardiotoxicity and optimize cardio-protection for improved patient heart health.”

Dr. Daniel J. Lenihan, MD, Professor of Cardiovascular Medicine, Cardio-Oncology Center Excellence Director at Washington University School of Medicine in St. Louis and study author, commented: “This study highlights the crucial role that MyoStrain technology may have for the early detection and prediction of cardiotoxicity during chemotherapy. We feel this could have a profound impact on patient care, focusing on optimizing heart health while also treating patients with lifesaving cancer therapy that has been shown to be cardiotoxic. With this approach, we hope to help extend patient longevity and improve quality of life.”

Access to the publication is available here.

[1] Guisca, S et al. Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. Circulation. 2021;14:e012459

Media Contact

Taylor Solomon

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 500 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit or connect with us on LinkedIn and Twitter @myocardialsoln.